KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (Weighted Average) (2016 - 2026)

Pacira BioSciences has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $40.5 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) fell 12.56% year-over-year to $40.5 million; the TTM value through Mar 2026 reached $40.5 million, down 12.56%, while the annual FY2025 figure was $44.6 million, 3.63% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $40.5 million at Pacira BioSciences, down from $44.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $46.5 million in Q1 2024 and troughed at $40.5 million in Q1 2026.
  • A 5-year average of $45.4 million and a median of $45.9 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 3.05% in 2022 and later decreased 12.56% in 2026.
  • Year by year, Shares Outstanding (Weighted Average) stood at $45.5 million in 2022, then increased by 1.54% to $46.2 million in 2023, then increased by 0.05% to $46.2 million in 2024, then dropped by 3.63% to $44.6 million in 2025, then decreased by 9.21% to $40.5 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PCRX at $40.5 million in Q1 2026, $44.6 million in Q4 2025, and $44.0 million in Q3 2025.